2018
DOI: 10.1530/jme-18-0024
|View full text |Cite
|
Sign up to set email alerts
|

Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture

Abstract: Glucocorticoid hormones (GCs) have profound effects on bone metabolism. Via their nuclear hormone receptor – the GR – they act locally within bone cells and modulate their proliferation, differentiation, and cell death. Consequently, high glucocorticoid levels – as present during steroid therapy or stress – impair bone growth and integrity, leading to retarded growth and glucocorticoid-induced osteoporosis, respectively. Because of their profound impact on the immune system and bone cell differentiation, GCs a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
35
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 65 publications
(36 citation statements)
references
References 128 publications
(173 reference statements)
0
35
0
1
Order By: Relevance
“…Osteocytes as the major source of RANKL; thyroid hormones; PTH/PTHrP; calcitriol; glucocorticoids; growth factors (FGF, PDGF, EGF); TNF-α; colony-stimulating factors (M-CSF, GM-CSF); IL-1, -6, -7 -8, -11, -15, -17;PGE1, 2, 12;PGH2 (MacDonald, 1986;Dempster et al, 1993;Raisz, 1993;Kawaguchi et al, 1994Kawaguchi et al, , 1995Nash et al, 1994;Holt et al, 1996;Lanske et al, 1999;Roodman, 1999;Lam et al, 2000;Compston, 2001;Ragab et al, 2002;Sher et al, 2004;Eijken et al, 2005;Dai et al, 2006;Zhang et al, 2008;Kini and Nandeesh, 2012;Rauner et al, 2012;Parra-Torres et al, 2013;Paiva and Granjeiro, 2017;Hachemi et al, 2018;Bellido and Gallant, 2019).…”
Section: Systemic and Local Factors That Stimulate Bone Resorptionmentioning
confidence: 99%
“…Osteocytes as the major source of RANKL; thyroid hormones; PTH/PTHrP; calcitriol; glucocorticoids; growth factors (FGF, PDGF, EGF); TNF-α; colony-stimulating factors (M-CSF, GM-CSF); IL-1, -6, -7 -8, -11, -15, -17;PGE1, 2, 12;PGH2 (MacDonald, 1986;Dempster et al, 1993;Raisz, 1993;Kawaguchi et al, 1994Kawaguchi et al, , 1995Nash et al, 1994;Holt et al, 1996;Lanske et al, 1999;Roodman, 1999;Lam et al, 2000;Compston, 2001;Ragab et al, 2002;Sher et al, 2004;Eijken et al, 2005;Dai et al, 2006;Zhang et al, 2008;Kini and Nandeesh, 2012;Rauner et al, 2012;Parra-Torres et al, 2013;Paiva and Granjeiro, 2017;Hachemi et al, 2018;Bellido and Gallant, 2019).…”
Section: Systemic and Local Factors That Stimulate Bone Resorptionmentioning
confidence: 99%
“…Diabetogenic effects, which include increased blood glucose levels, gluconeogenesis, glycogen storage, insulin secretion and/or liver metabolic enzyme transcription are mediated by GR transactivation and requires GR dimerization, were not observed with GR dim (63, 100, 101) or with CpdA (82, 97, 102104). While, osteoporosis, mediated by both transrepression (osteocalcin transcription) and transactivation (osteoblast differentiation) and thus requiring both GR monomers and dimers (95), was not induced by CpdA, either in vitro or in vivo (105109), while the GR dim mice still developed osteoporosis concomitant with a potent suppression of osteoblast differentiation both in vitro and in vivo (110112).…”
Section: Impact Of Gr Dimerization On the Therapeutic Index Of Glucocmentioning
confidence: 99%
“…Despite their unmistakable advantages, therapeutic treatment with glucocorticoids causes metabolic alterations which can lead to insulin resistance, and other problems, e.g., high blood pressure (6, 7). Treatment induced bone fragility partly results from direct effects of excess glucocorticoids on bone forming osteoblasts, which show reduced proliferation (8, 9). In addition, pro-osteoclastogenic effects and changes in other organ systems may contribute to glucocorticoid-induced bone loss (5).…”
Section: Introductionmentioning
confidence: 99%